Hidradenitis
12
1
2
4
Key Insights
Highlights
Success Rate
57% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
25.0%
3 terminated out of 12 trials
57.1%
-29.4% vs benchmark
0%
0 trials in Phase 3/4
75%
3 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 4 completed trials
Clinical Trials (12)
A Study to Investigate Efficacy and Safety of Duvakitug in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
Anifrolumab for Hidradenitis Suppurativa
SAR447971 First-in-human Study
Proof-of-concept Study Evaluating Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
Evaluate Safety and Pharmacokinetics of INF904 in Subjects With Moderate to Severe Chronic Spontaneous Urticaria or Hidradenitis Suppurativa
HIDRAdenitis Suppurativa and HEART Disease
HidraWear Study for Hidradenitis Suppurativa Wounds
Wound Etiology and Healing Study
Low Dose Radiotherapy for Advanced Hidradenitis Suppurativa
Hydroxychloroquine for the Treatment of Hidradenitis Suppurativa
Patients With Hidradenitis vs Patients With Psoriasis: Psychological Impact
Group Psychotherapy for Patients With Hidradenitis Suppurativa: Effects in Quality of Life